Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 112772

Result Summary for 112772

Result Summary

Protocol ID:	112772
Clinical Study ID:	112772
Official Title:	Follow-up study to evaluate the long-term immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV (580299) vaccine in healthy female subjects
Phase:	phase 3
Study Indications or Diseases:	Human Papillomavirus (HPV)
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Schwarz TF et al. Persistence of immune response 5 years after administration of HPV-16/18 AS04-adjuvanted vaccine to women aged 15–55 years. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia - 2011 Interim Conference (AOGIN). Bali, Indonesia, 17-19 March 2011. Schwarz TF et al. Persistence of immune response 6 years after administration of the HPV-16/18 AS04-adjuvanted vaccine to women aged 15–55 years. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN), Hong Kong, 13-15 July 2012.